Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-10
2007-07-10
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S267000
Reexamination Certificate
active
10069431
ABSTRACT:
The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.
REFERENCES:
patent: 5641866 (1997-06-01), Reed et al.
patent: 5643727 (1997-07-01), Reed et al.
patent: 5659024 (1997-08-01), Reed et al.
patent: 5686595 (1997-11-01), Reed et al.
patent: 5702897 (1997-12-01), Reed et al.
patent: 5734033 (1998-03-01), Reed
patent: 5744310 (1998-04-01), Reed
patent: 5994564 (1999-11-01), Van Sickle
patent: 5998583 (1999-12-01), Korsmeyer
patent: 6355660 (2002-03-01), Ricks et al.
patent: 1 054 011 (2000-11-01), None
patent: 7-196489 (1995-08-01), None
patent: 5-155877 (2003-06-01), None
patent: WO 99/40081 (1999-08-01), None
patent: WO 01/05769 (2001-01-01), None
Huang, Bcl-2 family proteins as targets for anticancer drug design, Oncogene (2000) 19, 6627-6631.
Tzung, Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3, Nature Cell Biology, vol. 3, (2001) 183-191.
Tokuatke et al., “Inhibition Of Electron Transport Of Rat-Liver Mitochondria By Synthesized Antimycin A Analog,”Biochimica et Biophysica Acta1142:262-268 (1993).
Tzung et al., “Antimycin A Mimics A BH3 Domain-Containing Peptide And Selectively Induces Apoptosis In Cell Lines Overexpressing Bcl-x13,”Proc. Accr-NCI EORTC International Conference, Molecular Targets And Cancer Therapeutics38155-38165 (1999).
Bernardi et al., “The permeability transition pore. Control points of a cyclosporine A-sensitive mitochondrial channel involved in cell death,”Biochim. Biophys. Acta1275:5-9 (1996).
Charlotte et al., “Immunohistochemical detection ofbcl-2 protein in normal and pathological human liver,”Am. J. Pathol.144:460-65 (1994).
Cheng et al., “Conversion of Bcl-2 to a Bax-like death effector by caspases,”Science278:1966-68 (1997).
Chittenden et al., “A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions,”EMBO J.14:5589-96 (1995).
Clem et al., “Modulation of cell death by Bcl-XLthrough caspase interaction,”Proc. Natl. Acad. Sci. USA95:554-59 (1998).
Cosulich et al., “Regulation of apoptosis by BH3 domains in a cell-free system,”Curr Biol.7:913-20 (1997).
Cosulich et al., “Bcl-2 regulates amplification of caspase activation by cytochrome c,”Curr Biol.9:147-50 (1999).
Decaudin et al., “Bcl-2 and Bcl-XLantagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents,”Cancer Res.57:62-67 (1997).
Fisher et al., “Apoptosis in cancer therapy: crossing the threshold,”Cell78:539-42 (1994).
Holinger et al., “Bak-BH3 peptides antagonize Bcl-XLfunction and induce apoptosis through cytochromec-independent activation of caspases,”J Biol. Chem.274:13298-304 (1999).
Hu et al., “Bcl-XLinteracts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation,”Proc. Natl. Acad. Sci. USA95:4386-91 (1998).
Hueber et al., “Thy-1 triggers mouse thymocyte apoptosis through abcl-2-resistant mechanism,”J. Exp. Med.179:785-96 (1994).
Hunter et al., “A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis,”J. Biol. Chem.271:8521-24 (1996).
Kelekar et al., “Bcl-2-family proteins: the role of the BH3 domain in apoptosis,”Trends Cell Biol. 8:324-30 (1998).
Kluck et al., “The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis,”Science275:1132-36 (1997).
Kroemer et al., “Mitochondrial control of apoptosis,”Immunol. Today18:44-51 (1997).
Kroemer, “The proto-oncogene Bcl-2 and its role in regulating apoptosis,”Nature Med.3:614-20 (1997).
Liu et al., “Induction of apoptotic program in cell-free extracts: requirement of dATP and cytochrome c,”Cell86:147-57 (1996).
Memon et al., “Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma,”J. Immunol.155:4644-52 (1995).
Minn et al., “Expression of Bcl-xLcan confer a multidrug resistance phenotype,”Blood86:1903-10 (1995).
Miyoshi et al., “A model of antimycin A binding based on structure-activity studies of synthetic antimycin A analogues,”Biochim. Biophys. Acta1229:149-54 (1995).
Muchmore et al., “X-ray and NMR structure of human Bcl-XLan inhibitor of programmed cell death,”Nature381:335-41 (1996).
Newmeyer et al., “Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria,”Cell79:353-64 (1994).
Pan et al., “Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex,”J. Biol. Chem.273:5841-5 (1998).
Petit et al., “Mitochondria and programmed cell death: back to the future,”FEBS Letters396:7-13 (1996).
Rieske, “Inhibitors of respiration at energy-coupling site 2 of the respiratory chain,”Pharm Ther.11:415-50 (1980).
Sattler et al., “Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis,”Science275:983-86 (1997).
Shimano et al., “Total synthesis of the antifungal dilactones UK-2A and UK-3A: the determination of their relative and absolute configurations, analog synthesis and antifungal activities,”Tetrahedron54:12745-74 (1998).
Susin et al., “Bcl-2 inhibits the mitochondrial release of an apoptogenic protease,”J. Exp. Med.184:1331-41 (1996).
Susin et al., “The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis,”J. Exp. Med.186:25-37 (1997).
Tokutake et al., “Inhibition of electron transport of rat-liver mitochondria by synthesized antimycin A analogs,”Biochim. Biophys. Acta1142:262-68 (1993).
Tokutake et al., “Structural factors of antimycin A molecule required for inhibitor action,”Biochim. Biophys. Acta1185:271-79 (1994).
Tzung et al., “Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as delayed early response gene,”Am. J. Pathol.150:1985-95 (1997).
van Tamelen et al., “The chemistry of antimycin A. X. Structure of the Antimycins,”J. Am. Chem. Soc.83:1639-1646 (1961).
Wu et al., “Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor α,”Proc. Natl. Sci. USA91:674-78 (1994).
Wu et al., “Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor α,”Cancer Res.54:5964-73 (1994).
Xia et al., “Electrical stimulation of neonatal cardiomyocytes results in the sequential activation of nuclear genes governing mitochondrial proliferation and differentiation,”Proc. Natl. Acad. Sci. USA94:11399-404 (1997).
Zamzami et al., “Sequential reduction of mitochondrial transmemberane potential and generation of reactive oxygen species in early programmed cell death,”J. Exp. Med.182:367-77 (1995).
Zamzami et al., “Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis,”FEBS Letters384:53-57 (1996).
Zamzami et al., “Mitochondrial control of nuclear apoptosis,”J. Exp. Med.183:1533-44 (1996).
Zoratti et al., “The mitochondrial permeability transition,”Biochim. Biophys. Act
Hockenberry David M.
Simon Julian A.
Tzung Shie-Pon
Fred Hutchinson Cancer Research Center
Owens Amelia A.
LandOfFree
Compositions and methods for modulating apoptosis in cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modulating apoptosis in cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulating apoptosis in cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3765748